Bot Chart, page-408

True, yet possible. As it was pointed out, some quite experienced analysts reckons that 'alternative' approaches are just as good as TA in predicting the future.
In any case we are going towards our date of reckoning with BOT. As I've already mentioned, the results of the psoriasis trial shall be indicative of those for the eczema's trial too as the two conditions are both T-cell mediated inflammatory diseases. And in a few months there's the first of two major game changers: if results are good BOT will undergo an irrevocable appreciation, beyond your 34-36c vision.
To put it simply: BOT is the world leading biotech when it comes to dermatological applications of cannabinoids: years ahead in a giaenormous market dominated by large corporations awash with cash.